ⓘ Growth momentum not rated — will be included automatically as data accumulates
Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech
The 52-week closing range appears once a full year of trading days has accumulated.
Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.
As of the Aug 31, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.
A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.
Valuation uses the Aug 31, 2026 close and market cap
Based on the FY2025 annual report · year-over-year comparison · determined on Sep 1, 2026
Of 9 items: 4 met · 3 not met · 2 not computable
Not metMetNot computable
Not computed — share count data is unavailable
Not computed — the denominator is zero or negative
A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (separate) — view original ↗
Methodology version change (v2.0 applied)
First calculation
Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.
Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.
Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.
Disclosed a paid-in capital increase (일반공모증자) issuing 2,060,000 new shares, equal to 17.7% of shares outstanding before the increase (filed 2025-12-05). View filing ↗
Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).
Determined as of 2026-09-01